AstraZeneca PLC and partner Merck & Co., Inc. have added a first-in-class indication to PARP inhibitor Lynparza’s (olaparib) US label, making the drug the first approved adjuvant therapy for early, high-risk breast cancer patients with BRCA mutations.
One of two PARP inhibitors approved in breast cancer – along with Pfizer Inc.’s Talzenna (talazoparib) – Lynparza is...